Specifically, we fused FEN1, EXO1, and a truncated EXO1 variant (HEX-N2 domain) to the PEmax using either 16-amino acid or 4-amino acid linkers as part of our therapeutic development strategy for cystic fibrosis treatment. Here, EXO1 is linked to cystic fibrosis.